Notwithstanding positive clinical evidence, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing significant opposition from managed care entities. Such organizations are often creating obstacles to reimbursement, such as significant price criteria and prior authorization that limit consumer opp